Cargando…

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia

A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage therapy for these patients. We studied all adult pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canaani, Jonathan, Nagar, Meital, Heering, Gabriel, Gefen, Chen, Yerushalmi, Ronit, Shem-Tov, Noga, Volchek, Yulia, Merkel, Drorit, Avigdor, Abraham, Shimoni, Avichai, Amariglio, Ninette, Rechavi, Gidi, Nagler, Arnon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289527/ https://www.ncbi.nlm.nih.gov/pubmed/32577167 http://dx.doi.org/10.18632/oncotarget.27618

Ejemplares similares

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
por: Heering, G., et al.
Publicado: (2022)

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Miller, Liron, et al.
Publicado: (2023)

P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Fried, S., et al.
Publicado: (2022)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Characterizing T Cells in SCID Patients Presenting with Reactive or Residual T Lymphocytes
por: Lev, Atar, et al.
Publicado: (2012)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
por: Ostrovsky, Olga, et al.
Publicado: (2018)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Evaluation of the clinical impact of bone marrow cultures in current medical practice
por: Sharvit, Gal, et al.
Publicado: (2022)

P1571: EVALUATION OF THE CLINICAL IMPACT OF BONE MARROW CULTURES IN CURRENT MEDICAL PRACTICE
por: Sharvit, G., et al.
Publicado: (2022)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

G23D: Online tool for mapping and visualization of genomic variants on 3D protein structures
por: Solomon, Oz, et al.
Publicado: (2016)

SurviveAI: Long Term Survival Prediction of Cancer Patients Based on Somatic RNA-Seq Expression
por: Nayshool, Omri, et al.
Publicado: (2022)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Cell Free Expression of hif1α and p21 in Maternal Peripheral Blood as a Marker for Preeclampsia and Fetal Growth Restriction
por: Ashur-Fabian, Osnat, et al.
Publicado: (2012)

Mutation analysis of the ferritin L-chain gene in age-related cataract
por: Assia, Nurit, et al.
Publicado: (2010)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
por: Wang, Amy Y., et al.
Publicado: (2018)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease
por: Beider, Katia, et al.
Publicado: (2017)

ADAR1 is vital for B cell lineage development in the mouse bone marrow
por: Marcu-Malina, Victoria, et al.
Publicado: (2016)

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
por: Braess, Jan, et al.
Publicado: (2018)

Mutagen-Specific Mutation Signature Determines Global microRNA Binding
por: Greenberg, Eyal, et al.
Publicado: (2011)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Identification of RNA editing sites in the SNP database
por: Eisenberg, Eli, et al.
Publicado: (2005)

Genome-wide activation of latent donor splice sites in stress and disease
por: Nevo, Yuval, et al.
Publicado: (2012)

Two Faces of Chondroitin Sulfate Proteoglycan in Spinal Cord Repair: A Role in Microglia/Macrophage Activation
por: Rolls, Asya, et al.
Publicado: (2008)

The Kinetics of Early T and B Cell Immune Recovery after Bone Marrow Transplantation in RAG-2-Deficient SCID Patients
por: Lev, Atar, et al.
Publicado: (2012)

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death
por: Josefsberg Ben-Yehoshua, Liat, et al.
Publicado: (2012)

Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis
por: Elkon, Ran, et al.
Publicado: (2005)

CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34(+) Cell Mobilization
por: Ostrovsky, Olga, et al.
Publicado: (2021)

Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations
por: Vecsler, Manuela, et al.
Publicado: (2011)

Consistent levels of A-to-I RNA editing across individuals in coding sequences and non-conserved Alu repeats
por: Greenberger, Shoshana, et al.
Publicado: (2010)

The HPSE Gene Insulator—A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease
por: Ostrovsky, Olga, et al.
Publicado: (2021)

The Effect of Gentamicin-Induced Readthrough on a Novel Premature Termination Codon of CD18 Leukocyte Adhesion Deficiency Patients
por: Simon, Amos J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_c13km9ab9rv50bfi74hbis0qil